Background: Secondary pulmonary hypertension (PH) and cor pulmonale are the major clinical cardiovascular complications affecting prognosis in patients with chronic obstructive pulmonary disease (COPD). It is also known that endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by the pulmonary vascular endothelium, and ET-1 may be implicated in the pathogenesis of PH. Objectives: The purpose of this study was to investigate the presence of ET-1 in patients with COPD and to assess the correlation of ET-1 levels in the plasma and bronchoalveolar lavage (BAL) fluid (BALF) in COPD patients with or without PH. Methods: Twenty-two patients with COPD and 15 healthy controls were enrolled in the study. Peripheral venous blood samples were collected in all patients and controls. BAL was obtained in COPD patients, and ET-1 levels were measured by radioimmunoassay in all plasma and BALF samples. Results: Plasma ET-1 levels were 2.46 ± 0.55 and 1.70 ± 0.42 pmol/dl in patients with COPD and controls, respectively (p < 0.0001). Sixteen of the 22 patients with COPD (73%) had PH established by echocardiography. The ET-1 level in these patients amounted to 2.59 ± 0.50 pmol/dl, and it was 2.10 ± 0.54 pmol/dl in 6 patients with COPD without PH. In COPD patients with and without PH, BALF ET-1 levels were 0.19 ± 0.08 and 0.24 ± 0.01 pmol/dl, respectively (p > 0.05). Conclusions: These results suggest that ET-1 is detectable in both the peripheral blood and BALF of COPD patients, but the levels do not statistically differ between patients with and without PH.

Keywords:
Bronchoalveolar lavage, Chronic obstructive pulmonary disease, Endothelin-1, Plasma, Pulmonary hypertension
1.
Roland M, Bhowmik A, Sapsford RJ, Seemungal TAR, Jeffries DJ, Warner TD, Wedzicha JA: Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001;56:30–35.
2.
Giaid A: Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 1998;114:208–212.
3.
Reichenberger F, Schauer J, Kellöner K, Sack U, Stiehl P, Winkler J: Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001;179:163–174.
4.
Sofia M, Maniscalco M, Celentano L, Farone S, Mormile M, Alifano M, Carratu L: Abnormalities of renal endothelin during acute exacerbation in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2001;14:321–327.
5.
British Thoracic Society: BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(suppl 5): S1–S28.
6.
Davidson CJ, Bonow RO: Cardiac catheterization in hearth disease; in Braunwald E, Zipes D, Libby P (eds): A Textbook of Cardiovascular Medicine, ed 6. Philadelphia, Saunders, 2001, pp 359–387.
7.
Luscher TF, Boulanger CM, Dohi Y, Yang Z: Endothelium derived contracting factors. Hypertension 1992;19:117–130.
8.
Stewart DJ, Levy R, Cernacek P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension – Marker or mediator of disease? Ann Intern Med 1991;114:464–469.
9.
Faller M, Kessler R, Sapin R, Chaouat A, Ehrhart M, Ducolone A, Weitzenblum E: Regulation of endothelin-1 at rest and during a short steady state exercise in 21 COPD patients. Pulm Pharmacol Ther 1998;11:151–157.
10.
Ferri C, Bellini C, Angelis CD, Siati LD, Perone A, Properzi G, Santucci A: Circulating endothelin-1 concentration in patients with chronic hypoxia. J Clin Pathol 1995;48:519–524.
11.
Cargill RI, Kiely DG, Clark RA, Lipworth BJ: Hypoxemia and release of endothelin-1. Thorax 1995;50:1308–1310.
12.
Fujii T, Otsuka T, Tanaka S, Kanazawa H, Hirata K, Kohno M, Kurihara N, Yoshikawa J: Plasma endothelin-1 level in chronic obstructive pulmonary disease: Relationship with natriuretic peptide. Respiration 1999;66:212–219.
13.
Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl B, Binder BR: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066–16068.
14.
Crestani B, Odoux C, Roland C, Moldovani F, Cornillet P, Fiet J, Aubier M: Hypoxia reduces endothelin production by rat alveolar type II cells in primary culture. Eur Respir J 1998;11:392–399.
15.
Jankov RP, Luo XP, Cabacungan J, Belcastro R, Frndova H, Lye SJ, Tanswell AK: Endothelin-1 and O2 mediated pulmonary hypertension in neonatal rats: A role for products of lipid peroxidation. Pediatr Respir 2000;48:289–298.
16.
Mattoli S, Soloperto M, Marini M, Fasoli A: Levels of endothelin in the bronchoalveolar lavage fluid of patients with symptomatic asthma and reversible airflow obstruction. J Allergy Clin Immunol 1991;88:375–383.
17.
Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH: Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Am Rev Respir Dis 1993;148:519–522.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.